VTCN1 and cancer: Considering the widespread expression of B7-H4 in different cancer types and low expression in normal tissues, B7-H4 is a reasonable target for the blockades, in which monotherapy such as CD3 bispecific antibody (BsAb) has proven effective in mouse models [57].